TY - JOUR AU - Prins, M. H. AU - Lensing, A. W. A. AU - Bauersachs, R. AU - van Bellen, B. AU - Bounameaux, H. AU - Brighton, T. A. PY - 2013 DA - 2013// TI - Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies JO - Thromb J VL - 11 UR - https://doi.org/10.1186/1477-9560-11-21 DO - 10.1186/1477-9560-11-21 ID - Prins2013 ER - TY - JOUR AU - Monagle, P. AU - Ignjatovic, V. AU - Savoia, H. PY - 2010 DA - 2010// TI - Hemostasis in neonates and children: pitfalls and dilemmas JO - Blood Rev VL - 24 UR - https://doi.org/10.1016/j.blre.2009.12.001 DO - 10.1016/j.blre.2009.12.001 ID - Monagle2010 ER - TY - JOUR AU - Attard, C. AU - Monagle, P. AU - Kubitza, D. AU - Ignjatovic, V. PY - 2012 DA - 2012// TI - The in vitro anticoagulant effect of rivaroxaban in children JO - Thromb Res VL - 130 UR - https://doi.org/10.1016/j.thromres.2012.07.009 DO - 10.1016/j.thromres.2012.07.009 ID - Attard2012 ER - TY - JOUR AU - Attard, C. AU - Monagle, P. AU - Kubitza, D. AU - Ignjatovic, V. PY - 2014 DA - 2014// TI - The in-vitro anticoagulant effect of rivaroxaban in neonates JO - Blood Coagul Fibrinolysis VL - 25 UR - https://doi.org/10.1097/MBC.0000000000000033 DO - 10.1097/MBC.0000000000000033 ID - Attard2014 ER - TY - JOUR AU - Kearns, G. L. AU - Abdel-Rahman, S. M. AU - Alander, S. W. AU - Blowey, D. L. AU - Leeder, J. S. AU - Kauffman, R. E. PY - 2003 DA - 2003// TI - Developmental pharmacology-drug disposition, action, and therapy in infants and children JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMra035092 DO - 10.1056/NEJMra035092 ID - Kearns2003 ER - TY - JOUR AU - Willmann, S. AU - Becker, C. AU - Burghaus, R. AU - Coboeken, K. AU - Edginton, A. AU - Lippert, J. PY - 2014 DA - 2014// TI - Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban JO - Clin Pharmacokinet VL - 53 UR - https://doi.org/10.1007/s40262-013-0090-5 DO - 10.1007/s40262-013-0090-5 ID - Willmann2014 ER - TY - BOOK AU - Bayer, A. G. PY - 2018 DA - 2018// TI - Xarelto® (rivaroxaban) Summary of Product Characteristics ID - Bayer2018 ER - TY - JOUR AU - Rohde, G. PY - 2008 DA - 2008// TI - Determination of rivaroxaban – a novel, oral, direct factor Xa inhibitor – in human plasma by high-performance liquid chromatography-tandem mass spectrometry JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 872 UR - https://doi.org/10.1016/j.jchromb.2008.07.015 DO - 10.1016/j.jchromb.2008.07.015 ID - Rohde2008 ER - TY - STD TI - Willmann S, Thelen K, Kubitza D, Lensing AWA, Frede M, Coboeken K, et al. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling – an EINSTEIN JUNIOR phase I study. Thrombosis J. 2018. https://doi.org/10.1186/s12959-018-0185-1. ID - ref9 ER - TY - JOUR AU - Yee, D. L. AU - O'Brien, S. H. AU - Young, G. PY - 2013 DA - 2013// TI - Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients JO - Clin Pharmacokinet VL - 52 UR - https://doi.org/10.1007/s40262-013-0094-1 DO - 10.1007/s40262-013-0094-1 ID - Yee2013 ER - TY - JOUR AU - Corbella, E. AU - Miragliotta, G. AU - Masperi, R. AU - Villa, S. AU - Bini, A. AU - de Gaetano, G. PY - 1979 DA - 1979// TI - Platelet aggregation and antithrombin III levels in diabetic children JO - Haemostasis VL - 8 ID - Corbella1979 ER - TY - JOUR AU - Fukui, H. AU - Taniguchi, A. AU - Sakamoto, S. AU - Kawahara, S. AU - Matsunaga, T. AU - Taira, K. PY - 1989 DA - 1989// TI - Antithrombin III in children with various renal diseases JO - Pediatr Nephrol VL - 3 UR - https://doi.org/10.1007/BF00852896 DO - 10.1007/BF00852896 ID - Fukui1989 ER - TY - JOUR AU - Singh, R. R. AU - Gupte-Singh, K. R. AU - Wilson, J. P. AU - Moffett, B. S. PY - 2016 DA - 2016// TI - Adherence to anticoagulant therapy in pediatric patients hospitalized with pulmonary embolism or deep vein thrombosis: a retrospective cohort study JO - Clin Appl Thromb Hemost VL - 22 UR - https://doi.org/10.1177/1076029615601493 DO - 10.1177/1076029615601493 ID - Singh2016 ER - TY - JOUR AU - Halton, J. M. AU - Lehr, T. AU - Cronin, L. AU - Lobmeyer, M. T. AU - Haertter, S. AU - Belletrutti, M. PY - 2016 DA - 2016// TI - Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study JO - Thromb Haemost VL - 116 UR - https://doi.org/10.1160/TH15-04-0275 DO - 10.1160/TH15-04-0275 ID - Halton2016 ER - TY - JOUR AU - Halton, J. M. L. AU - Albisetti, M. AU - Biss, B. AU - Bomgaars, L. AU - Brueckmann, M. AU - Gropper, S. PY - 2017 DA - 2017// TI - Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability JO - J Thromb Haemost VL - 15 UR - https://doi.org/10.1111/jth.13847 DO - 10.1111/jth.13847 ID - Halton2017 ER - TY - JOUR AU - Halton, J. M. L. AU - Picard, A. C. AU - Harper, R. AU - Huang, F. AU - Brueckmann, M. AU - Gropper, S. PY - 2017 DA - 2017// TI - Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism JO - Thromb Haemost VL - 117 UR - https://doi.org/10.1160/TH17-06-0429 DO - 10.1160/TH17-06-0429 ID - Halton2017 ER - TY - JOUR AU - Young, G. AU - Yee, D. L. AU - O'Brien, S. H. AU - Khanna, R. AU - Barbour, A. AU - Nugent, D. J. PY - 2011 DA - 2011// TI - FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age JO - Pediatr Blood Cancer VL - 57 UR - https://doi.org/10.1002/pbc.23011 DO - 10.1002/pbc.23011 ID - Young2011 ER - TY - JOUR AU - Young, G. AU - Tarantino, M. D. AU - Wohrley, J. AU - Weber, L. C. AU - Belvedere, M. AU - Nugent, D. J. PY - 2007 DA - 2007// TI - Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis JO - J Thromb Haemost VL - 5 UR - https://doi.org/10.1111/j.1538-7836.2007.02623.x DO - 10.1111/j.1538-7836.2007.02623.x ID - Young2007 ER - TY - JOUR AU - O'Brien, S. H. AU - Yee, D. L. AU - Lira, J. AU - Goldenberg, N. A. AU - Young, G. PY - 2015 DA - 2015// TI - UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis JO - J Thromb Haemost VL - 13 UR - https://doi.org/10.1111/jth.13057 DO - 10.1111/jth.13057 ID - O'Brien2015 ER - TY - JOUR AU - Forbes, T. J. AU - Hijazi, Z. M. AU - Young, G. AU - Ringewald, J. M. AU - Aquino, P. M. AU - Vincent, R. N. PY - 2011 DA - 2011// TI - Pediatric catheterization laboratory anticoagulation with bivalirudin JO - Catheter Cardiovasc Interv VL - 77 UR - https://doi.org/10.1002/ccd.22817 DO - 10.1002/ccd.22817 ID - Forbes2011 ER - TY - JOUR AU - Young, G. AU - Boshkov, L. K. AU - Sullivan, J. E. AU - Raffini, L. J. AU - Cox, D. S. AU - Boyle, D. A. PY - 2011 DA - 2011// TI - Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study JO - Pediatr Blood Cancer VL - 56 UR - https://doi.org/10.1002/pbc.22852 DO - 10.1002/pbc.22852 ID - Young2011 ER - TY - JOUR AU - Howie, S. R. C. PY - 2011 DA - 2011// TI - Blood sample volumes in child health research: review of safe limits JO - Bull World Health Organ VL - 89 UR - https://doi.org/10.2471/BLT.10.080010 DO - 10.2471/BLT.10.080010 ID - Howie2011 ER -